Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (2016 - 2025)

KalVista Pharmaceuticals' Shares Outstanding history spans 11 years, with the latest figure at $49.8 million for Q2 2025.

  • On a quarterly basis, Shares Outstanding rose 17.03% to $49.8 million in Q2 2025 year-over-year; TTM through Apr 2025 was $49.8 million, a 17.03% increase, with the full-year FY2025 number at $49.8 million, up 17.03% from a year prior.
  • Shares Outstanding hit $49.8 million in Q2 2025 for KalVista Pharmaceuticals, up from $49.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding for KALV hit a ceiling of $49.8 million in Q2 2025 and a floor of $18.0 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $37.1 million across 4 years, with a median of $34.6 million in 2024.
  • The widest YoY moves for Shares Outstanding: up 36.85% in 2021, down 0.98% in 2021.
  • Tracing KALV's Shares Outstanding over 4 years: stood at $24.4 million in 2021, then skyrocketed by 40.94% to $34.4 million in 2023, then surged by 43.61% to $49.4 million in 2024, then rose by 0.66% to $49.8 million in 2025.
  • Business Quant data shows Shares Outstanding for KALV at $49.8 million in Q2 2025, $49.4 million in Q4 2024, and $43.3 million in Q4 2024.